Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2019 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call

AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
February 06, 2019 00:15 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering

AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
February 05, 2019 17:15 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
December 11, 2018 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency

Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expected to Initiate in Q2 2019; Topline Data Anticipated in Q1 2021 Company to Host Conference Call...
December 06, 2018 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference

AUSTIN, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
November 20, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference

AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
November 08, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

AUSTIN, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
October 26, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting

AEB5100 is an Engineered Human Enzyme with Novel Cystine Degrading Activity Presentation Today at 5:54 p.m. PT at the 2018 American Society of Nephrology (ASN) Annual Meeting AUSTIN, Texas, Oct. ...
October 22, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress

Pegzilarginase Monotherapy Demonstrates Anti-Tumor Activity AUSTIN, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company...
October 19, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference

AEB4104 is a Novel Engineered Human Enzyme with Unique Specificity for Degrading Both Homocysteine and Homocystine AEB4104 Prevents Death, Stops Disease Progression, and Reverses Liver Pathology in a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right